Board of Trustees of The Leland Stanford Junior University’s ARS Pharmaceuticals SPRY Stock Holding History

Board of Trustees of The Leland Stanford Junior University’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-14,515	Closed	-$97K	–	47
2021 Q4	$97K	Hold	14,515	–	–	0.01%	41
2021 Q3	$145K	Sell	14,515 -7,225	-33%	-$178K	0.01%	40
2021 Q2	$672K	Hold	21,740	–	–	0.06%	26
2021 Q1	$949K	Hold	21,740	–	–	0.08%	19
2020 Q4	$1.01M	Buy	+21,740	New	+$726K	0.07%	12

Other funds holding SPRY

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Board of Trustees of The Leland Stanford Junior University's SPRY Position: Q1 2022 in Review

Board of Trustees of The Leland Stanford Junior University sold out of ARS Pharmaceuticals (SPRY) in Q1 2022, closing a stake of 14,515 shares — an estimated $97K sold.

Board of Trustees of The Leland Stanford Junior University first reported a position in SPRY in Q4 2020 and held it in 5 quarters. The position peaked at $1.01M in Q4 2020. 70 funds tracked by Wall St. Rank hold SPRY as of Q1 2022.

Board of Trustees of The Leland Stanford Junior University reported no remaining ARS Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Board of Trustees of The Leland Stanford Junior University sold 14,515 ARS Pharmaceuticals shares in Q1 2022, an estimated $97K.
Board of Trustees of The Leland Stanford Junior University first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 5 quarters.
Board of Trustees of The Leland Stanford Junior University's ARS Pharmaceuticals position peaked at $1.01M in Q4 2020.
70 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2022.

Based on Board of Trustees of The Leland Stanford Junior University's 13F filing for Q1 2022, filed 13 May 2022.